About Contact Us Careers
Sign In

Drug-resistant Tuberculosis Treatment Market - Top Companies and Manufacturers

  • Report ID: 6169
  • Published Date: Jun 12, 2024
  • Report Format: PDF, PPT

Companies Dominating the Drug-Resistant Tuberculosis Treatment Landscape

    The major players in the drug-resistant tuberculosis treatment market are offering a detailed portfolio of tuberculosis related medicines. These companies introduced advanced technologies that enable detailed visualization of test procedures.

    • Johnson & Johnson
    • Company Overview 
    • Business Strategy 
    • Key Product Offerings 
    • Financial Performance 
    • Key Performance Indicators 
    • Risk Analysis 
    • Recent Development 
    • Regional Presence 
    • SWOT Analysis 
    • Novartis AG
    • Sanofi SA
    • Endo International Plc
    • Lupin
    • Hikma Pharmaceuticals
    • Pfizer Inc.
    • STI Pharma LLC
    • ANI Pharmaceuticals
    • Thermo Fisher Scientific Inc.
Browse Key Market Insights with Data Illustration:

In the News

  • Lupin to reduce the burden of large TB patients from low-income countries and provide support for the prevention of TB, Lupin Limited has released an agreement in public with the Clinton Health Access Initiative (CHAI), the Unitaid, the Aurum Institute, and various other global procurement agencies.
  • ANI Pharmaceuticals proves the strength of its R&D engine by announcing the approval of Rifabutin Capsules USP, 150 mg by the US Food and Drug Administration (FDA).

Author Credits:  Radhika Pawar


  • Report ID: 6169
  • Published Date: Jun 12, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of drug-resistant tuberculosis treatment was over USD 1271.0 million.

The market size for drug-resistant tuberculosis treatment is projected to cross USD 1905.2 million by the end of 2036 expanding at a CAGR of 5.2% during the forecast period i.e., between 2024– 2036.

The major players in the market are Johnson & Johnson, Novartis AG, Sanofi SA, Endo International Plc, Lupin, Hikma Pharmaceuticals, Pfizer Inc., STI Pharma LLC, Ani Pharmaceuticals, Thermo Fisher Scientific Inc., and others.

The first-line anti-TB drugs segment is anticipated to garner a share of 60% during 2024–2036.

The North America drug-resistant tuberculosis treatment sector is poised to hold a 35% share by the end of 2036.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample